Arvada, N.A., Arvada, Colorado; FirstBank of Aurora, N.A., Aurora, Colorado; FirstBank of Avon, Avon, Colorado; FirstBank of Boulder, N.A., Boulder, Colorado; FirstBank of Breckenridge, N.A., Breckenridge, Colorado; FirstBank of Douglas County, N.A., Castle Rock, Colorado; FirstBank of Colorado Springs, Colorado Springs, Colorado; FirstBank of Cherry Creek, N.A., Denver, Colorado; FirstBank of Denver, N.A., Denver, Colorado; FirstBank of Longmont, Longmont, Colorado; FirstBank of Northern Colorado, Fort Collins, Colorado; FirstBank of Greeley, Greeley, Colorado; FirstBank of Tech Center, N.A., Englewood, Colorado; FirstBank of Colorado, N.A., Lakewood, Colorado; FirstBank of South Jeffco, Littleton, Colorado; FirstBank of Lakewood, N.A.,Lakewood, Colorado; FirstBank of Littleton, N.A., Littleton, Colorado; FirstBank of Arapahoe County, N.A., Littleton, Colorado; FirstBank of Silverthorne, N.A., Silverthorne, Colorado; FirstBank of Vail, Vail, Colorado; FirstBank North, N.A., Westminster, Colorado; FirstBank of Wheat Ridge, N.A., Wheat Ridge, Colorado; FirstBank of Evergreen, Evergreen, Colorado; and FirstBank, N.A., Palm Desert, California.

Board of Governors of the Federal Reserve System, September 12, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–24701 Filed 9–16–97; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Health Care Policy and Research

Contract Review Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C. Appendix 2), the Agency for Health Care Policy and Research (AHCPR) announces the following technical review committee to meet during the month of September 1997:

Name: Technical Review Committee for the AHCPR User Liaison Program Mail Key Support Services Contract.

Date and Time: September 24, 1997, 10 a.m.—3 p.m.

Place: Agency for Health Care Policy and Research Willco Building, 3rd Floor Conference Room 6000 Executive Boulevard Rockville, MD 20852.

This meeting will be closed to the public.

Purpose: The Technical Review Committee's charge is to provide, on behalf of the AHCPR Contracts Review Committee, recommendations to the Administrator, AHCPR, regarding the technical merit of contract proposals submitted in response to a specific Request for Proposals regarding the User Liaison Program (ULP) Mail Key Support Services contract.

The purpose of this contract is to provide for the timely merging and mailing of letters of invitation to User Liaison Program (ULP) workshops through use of a ULP developed, automated data base. The contractor will use and maintain a data base of State legislators, Governors and their staff, Federal and State executive branch, and local health officials, as well as selected public and private users of health services research including—health care consumers, purchasers, plans, practitioners, and policymakers. The contractor will perform mail merges for all letters of invitation and mail such invitations numbering between 3500 and 6000 as bulk mailings. Using the data in the database, the contractor will generate an annual *User Liaison Program Directory.* These services are required to ensure the timely dissemination of AHCPR research findings and related publications to the research community and general public.

Agenda: The Committee meeting will be devoted entirely to the technical review and evaluation of contract proposals submitted in response to the above referenced Request for Proposals. The Administrator, AHCPR, has made a formal determination that this meeting will not be open to the public. This action is necessary to protect the free and full exchange of views in the contract evaluation process and safeguard confidential proprietary information, and personal information concerning individuals associated with the proposals that may be revealed during the meeting. This action is taken in accordance with section 10(d) of the Federal Advisory Committee Act, 5 U.S.C., Appendix 2, 5 USC 522(b)(c)(6), 41 CFR 101–6.1023 and Department procurement regulations, 48 CFR 315.604(d).

Anyone wishing to obtain information regarding this meeting should contact Serena Toro, User Liaison Program, Center for Health Information Dissemination, Agency for Health Care Policy and Research, 2101 East Jefferson Street, Suite 401, Rockville, Maryland 20852, 301/594–6668.

Dated: September 11, 1997.

John M. Eisenberg,

Administrator.

[FR Doc. 97–24651 Filed 9–16–97; 8:45 am]

BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

Expert Workshop Regarding Medical Monitoring in Bunker Hill, ID; Meeting

The Agency for Toxic Substances and Disease Registry (ATSDR) announces the following meeting.

Name: Expert Workshop Regarding Medical Monitoring in Bunker Hill, ID.

Times and Dates: 8 a.m.–5 p.m., September 23–24, 1997.

Place: The D. Abbott Turner Center at Emory University, 703 Clifton Road, NE, Atlanta, GA 30329, telephone 404/712–6725.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: ATSDR is considering the appropriateness of medical monitoring for populations who lived around the former Bunker Hill lead smelting facility (the Bunker Hill Superfund Site) in the Silver Valley area of Idaho during a time of excess exposures of public health significance. As Page 2 part of this consideration process, ATSDR is convening a series of workshops to examine the appropriateness and feasibility of a medical monitoring program.

The purpose of the medical monitoring program is to provide a public health service to communities affected by exposures to hazardous substances. This is accomplished by screening target populations at significant risk of a specific health effect or outcome, identifying individuals in need of further diagnosis or treatment, and arranging for appropriate referrals.

Section 104(i)(9) of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), as amended (42 U.S.C. 9604(i)(9)), provides for the Administrator, ATSDR, to initiate a health surveillance program for populations at significantly increased risk of adverse health effects as a result of exposure to hazardous substances released from a facility. A program included under health surveillance is referred to as ''medical monitoring or screening'' by ATSDR and is defined in the legislation as ''the periodic medical testing to screen people at significant increased risk for disease.''

ATSDR has established criteria to determine when medical monitoring is an appropriate health activity and the requirements for establishing a medical monitoring program at a site. The legislation requires that a mechanism to refer people for treatment be included in the program. The statute does not authorize ATSDR to provide medical treatment; thus, medical monitoring is performed as a community service, not a health study.

ATSDR is convening three expert workshops to assist in the evaluation of a medical monitoring program at the Bunker Hill site. If a program is deemed appropriate, the Agency will develop a medical monitoring plan for the target population(s). The first workshop, was held on August 19–20, 1997. This notice announces the second workshop.

Matters to be Considered: The objective of this workshop is to use all available relevant data from ATSDR, including that produced by the first workshop, to make individual recommendations and answer questions related to:

(1) The analysis of specific outcomes as candidates for monitoring from the first workshop, (2) further definition of the target populations from the first workshop, (3) the consideration of other heavy metals exposures as moderators of lead-based medical monitoring recommendations, and

(4) medical decision analysis related to the Bunker Hill site. Scientists with expertise specific to the health outcomes under consideration will convene to define appropriate screening tests to be included in the medical monitoring program based on the proposed outcomes and eligible populations. Also, the workshop will provide ATSDR guidance in the development of clinical evaluation protocols that could be included in a medical monitoring program.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Vivian Rush, M.D., Medical Officer, ATSDR, Division of Health Education and Promotion, 1600 Clifton Road, NE, M/S E–33, Atlanta, Georgia 30333, telephone 404/639–5080 or Gregory Thomas, Senior Regional Representative, ATSDR Region X, Seattle, WA 98101, telephone 206/553–2113.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–24637 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Meetings

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following Fetal Alcohol Syndrome (FAS) Prevention meetings:

Name: 1997 Fetal Alcohol Syndrome (FAS) Surveillance and Prevention Grantees' Meeting.

Time And Date: 8 a.m.–5:30 p.m., September 25, 1997.

Place: Beaver Run Resort and Conference Center, 620 Village Road, Breckenridge, Colorado 80424, 970/453–6000.

Status: Open to CDC grantees conducting FAS epidemiologic surveillance and prevention projects among various States and universities. Persons in the general public wishing to participate may telephone 770/488–7268, e-mail (GCL1@cdc.gov) or fax (770/488–7361) their request.

Purpose: The annual meeting of CDC's FAS grantees is held in order to exchange information regarding the funded projects' activities and progress.

Matters To Be Discussed: Agenda items include a CDC update related to FAS epidemiologic surveillance and prevention activities, and summary reports from each of the grantees. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Gregg Leeman, Fetal Alcohol Syndrome Prevention Section, NCEH, CDC, 4770 Buford Highway, NE, MS:F15, Atlanta, Georgia 30341, telephone 770/488–7268, e-mail GCL1@cdc.gov, fax 770/488–7361.

Name: Prevention and Management: Fetal Alcohol Syndrome and Prenatal Substance Abuse, sponsored by the Colorado Fetal Alcohol and Substance Abuse Coalition and CDC's Division of Birth Defects and Developmental Disabilities.

Times And Dates: 3 p.m.–7 p.m., September 25, 1997; 7:30 a.m.–5 p.m., September 26, 1997; 7:30 a.m.–4:30 p.m., September 27, 1997.

Place: Beaver Run Resort and Conference Center, 620 Village Road, Breckenridge, Colorado 80424, 970/453–6000.

Status: Open. Persons wishing to participate in the conference may register by contacting Elizabeth Franz, telephone 303/756–8380; e-mail fasconf@aol.com; or fax 303/759–8861. The conference registration fee is $175.00.

Purpose: Conference objectives are to present: Effective models for identification of and intervention with high-risk women; current research on screening and diagnostic methods and interventions for the child prenatally exposed to alcohol; current public health and epidemiological data; current research about the effects of alcohol and other drugs on fetal development; to discuss policy, legal and criminal justice issues related to FAS; and to explore community-based prevention programs.

Matters To Be Discussed: The conference is built around six areas of emphasis: Intervention with high-risk women; Working with the FAS affected child; Public health and epidemiology; Clinical and research issues; Policy and legal issues; Community issues and prevention programs.

Contact Person For More Information: Elizabeth Franz, Colorado Fetal Alcohol and Substance Abuse Coalition Conference Office, telephone 303/756–8380, fax 303/759–8861, e-mail fasconf@aol.com.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–24635 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Council for the Elimination of Tuberculosis: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Advisory Council for the Elimination of Tuberculosis (ACET).

Times and Dates: 8:30 a.m.–5 p.m., October 16, 1997; 8:30 a.m.–12 p.m., October 17, 1997.

Place: Corporate Square Office Park, Corporate Square Boulevard, Building 11, Room 1413, Atlanta, Georgia 30329.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: The Council advises and makes recommendations to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis. Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews the extent to which progress has been made toward eliminating tuberculosis.

Matters to be Discussed: Agenda items include follow-up discussion on issues related to isoniazid prevention therapy; discussions on scientific basis of TB vaccine; TB vaccine development and implementation; economic issues relating to TB vaccines; and developing long term goals and/or issues of ACET. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Janet Cleveland, National Center for HIV, STD, and TB Prevention, 1600 Clifton Road, NE, M/S E–07, Atlanta, Georgia 30333, telephone 404/639–8008.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–24636 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0022]

Agency Information Collection Activities; Submission for OMB Review; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).

DATES: Submit written comments on the collection of information by October 17, 1997.

ADDRESSES: Submit written comments on the collection of information to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attention: Desk Officer for FDA.

FOR FURTHER INFORMATION CONTACT: Judith V. Bigelow, Office of Information